

Lignans

Guest Editor:

Assoc. Prof. David Barker

School of Chemical Sciences,
University of Auckland, Private
Bag 92019, Auckland, New
Zealand

d.barker@auckland.ac.nz

Deadline for manuscript
submissions:


closed (31 January 2019)

Message from the Guest Editor

Lignans are traditionally defined as a class of secondary metabolites that are derived from the dimerisation of two or more phenylpropanoid units. Despite their common biosynthetic origins, they boast a vast structural diversity. It is also well-established that this class of compounds exhibit a range of potent biological activities. Owing to these factors, lignans have proven to be a challenging and desirable synthetic target and has instigated the development of a number of different synthetic methods, advancing our collective knowledge towards the synthesis of complex and unique structures.

This Special Issue is focused on current research concerning this notable class of compounds, ranging in scope from recent isolation and structural elucidation of new and novel compounds, biosynthetic studies to explore their origins, total syntheses and strategies towards lignan synthesis, assessment of their biological activities and potential for further therapeutic development.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Derek J. McPhee

Senior Director, Technology
Strategy, Amyris, Inc., 5885 Hollis
St, Suite 100, Emeryville, CA
94608, USA

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 22nd year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed), Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 12.6 days after submission; acceptance to publication is undertaken in 4.4 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Molecules
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
@Molecules_MDPI